Navigation Links
ImpactRx Measures How Patient Brand Requests Drive Physician Treatment Decisions
Date:7/6/2011

MOUNT LAUREL, N.J., July 6, 2011 /PRNewswire/ -- ImpactRx, the pioneer in measuring the impact of promotion on physician prescribing behavior, offers pharmaceutical brand managers unique insight into the effectiveness of their direct-to-consumer promotional efforts.  ImpactRx's proprietary database, ImpactData™, annually captures more than 250,000 brand requests by patients.   ImpactRx then records physicians' treatment behavior in response to these requests from their patients.

ImpactRx's longitudinal research model provides information on changes in patient request trends over time.  Through the ImpactData, the effectiveness of a brand's DTC campaign can be quickly measured by the change in share of patient requests generated before and after the campaign's initiation.

Additionally, ImpactRx uniquely tracks how often physicians honor requests from their patients across all therapeutic areas.  The ImpactData documents that patient requests underlie a greater proportion of physician usage of lifestyle drugs for the treatment of conditions such as erectile dysfunction and smoking cessation than usage of medications for chronic conditions like high cholesterol or diabetes.  More than 20% of lifestyle treatments are associated with a patient request, while less than 5% of chronic medications have a corresponding request.  Physician fulfillment rates per patient request, however, are similar for most therapeutic areas.  Adding sample usage by physicians to their prescription writing increases the overall average fulfillment rate per request to about 85%.

Lesley Bailey, Senior Director, Product Development/Marketing at ImpactRx, stated, "although there are differences in degree across markets, our data clearly shows that patient requests influence physician behavior.  The longitudinal nature of our research model coupled with its physician-level linkage from request through to fulfillment, enables us to provide our clients unique insight into the effectiveness of their DTC campaigns," Bailey continued.  "To get a true read on the impact of their DTC efforts, our clients need to know not only if they are generating requests for their brands, but also if physicians are honoring those requests," said Bailey.

"The effectiveness of Uloric's recent DTC activity in the gout market is something we're watching closely," stated Bailey.  "Patients are requesting Uloric at higher-than-average rates, so the ultimate success of the brand's campaign will hinge on its ability to educate physicians to fulfill those requests," Bailey finished.

ImpactRx's panels span fourteen specialties including Primary Care, Oncology, Endocrinology, Cardiology, Rheumatology and Neurology.  New panels supporting Pulmonology and Adult Psychiatry were launched earlier this year.

About ImpactRx

Founded in 2000 and headquartered in Mount Laurel, N.J., ImpactRx's longitudinal panels of high value, iPhone-connected physicians are the exclusive source of continuously-captured promotion and treatment data. Through its proprietary methodology, the Company annually captures one million details and three-million treatment decisions, fueling its unique ImpactData™ industry database. ImpactRx is a private company with investment financing provided by Symphony Technology Group (www.symphonytg.com) and Merck Capital Ventures.  For more information, visit: www.impactrx.com.

CONTACT:  
Lesley Bailey
Senior Director, Product Development/Marketing
ImpactRx, Inc.
856-802-4133
lbailey@impactrx.com


'/>"/>
SOURCE ImpactRx
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. ImpactRx Tracks Decline in Zetia and Vytorin Prescribing
2. Kantar Health and ImpactRx Launch CancerMPact Monthly Drugs and Regimens for Oncology Business Decisions
3. ImpactRx Releases 2010 Oncology Promotion Report
4. ImpactRx Acquired by Symphony Technology Group
5. ImpactRx Expands Psychiatry Research Panel to Include Adolescent Psychiatrists
6. ImpactRx Names Kjell Nygren Vice President, Analytical Services
7. Boston Scientific PROMUS(TM) and TAXUS(R) Stents Continue Strong Performance in Safety and Efficacy Measures
8. PTC Therapeutics Announces Data Showing Six-Minute Walk Test Consistently Measures Ambulatory Function in Patients With Duchenne Muscular Dystrophy
9. ValueOptions(R) Supports New Hospital-Based Performance Measures to Help Patients Get the Best Treatment for Inpatient and Outpatient Services
10. Shire Announces Study Results of the Effects of INTUNIV(TM) (Guanfacine) Extended Release on Secondary Measures in Children with ADHD and Oppositional Symptoms
11. Abbotts XIENCE V(R) Superior to TAXUS(R) in Key Safety and Efficacy Measures in SPIRIT IV Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)...   Pulmatrix, Inc ., (NASDAQ: PULM ... announced today that it was added to the Russell ... comprehensive set of U.S. and global equity indexes on ... milestone for Pulmatrix," said Chief Executive Officer Robert ... progress in developing drugs for crucial unmet medical needs, ...
(Date:6/23/2016)... 23, 2016  MedSource announced today that it ... software solution of choice.  This latest decision demonstrates ... to their clients by offering a state-of-the-art electronic ... establishes nowEDC as the EDC platform of choice ... clients.  "nowEDC has long been a preferred EDC ...
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... the "Pharmaceutical Excipients Market by Type (Organic Chemical ... Preservative), Formulation (Oral, Topical, Coating, Parenteral) - Global Forecast ... The global pharmaceutical excipients ... 2021 at a CAGR of 6.1% in the forecast ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 26, 2016 , ... Pixel Film Studios Released ... , "Film editors can give their videos a whole new perspective by using the ... CEO of Pixel Film Studios. , ProSlice Levels contains over 30 Different presets ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery services, ... Mohs Surgery and to Dr. Russell Peckham for medical and surgical dermatology. , Dr. ... skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was ...
(Date:6/25/2016)... ... 25, 2016 , ... Dr. Calvin Johnson has dedicated his ... implemented orthobiologic procedures as a method for treating his patients. The procedure is ... to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use to help ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is ... associated with chronic pain and the benefits of holistic treatments, Serenity Recovery Center ... suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder of ...
(Date:6/24/2016)... San Diego, CA (PRWEB) , ... June 24, 2016 , ... ... up with the American Cancer Society and the Road To Recovery® program to drive ... care to seniors and other adults to ensure the highest quality of life and ...
Breaking Medicine News(10 mins):